Objective To observe the clinical effect of Venolazine in the treatment of reflux esophagitis(RE)after esophagogastric anastomosis.Methods A total of 60 patients with RE after esophagogastric anastomosis treated in our hospi-tal from January to October 2022 were randomly divided into the research group and the control group,with 30 cases in each group.The research group was treated with Venolazine and the control group was treated with Esomeprazole.The clinical effect at 4 weeks after treatment,biochemical indexes,frequency scale for the symptoms of gastroesophageal reflux disease(FSSG)scores before treatment and at 2 and 4 weeks after treatment,Los Angeles(LA)grading before treatment and at 4 weeks after treatment,adverse reactions during treatment and recurrence at 3 months after follow-up were compared between the two groups.Results At 4 weeks after treatment,the total effective rate of the research group was 93.33%(28/30),which was higher than that of the control group[73.33%(22/30)](P<0.05).At 2 and 4 weeks after treatment,serum tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),interleukin-23(IL-23),calcitonin gene-related peptide(CGRP),heme oxygenase-1(HO-1)and FSSG scores of the research group were lower than those of the control group,and serum glutathione(GSH)was higher than that of the control group(P<0.05).Before treatment and at 2 and 4 weeks after treatment,serum TNF-α,IL-1β,IL-23,CGRP,HO-1 and FSSG scores in the two groups were gradually decreased,while serum GSH was gradually increased(P<0.05).At 4 weeks after treatment,LA grading in both groups was improved com-pared with that before treatment(P<0.01).During treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).At 3 months after follow-up,the recurrence rate of the research group was 3.33%(1/30),which was lower than that of the control group[26.67%(8/30)](P<0.05).Conclusion The thera-peutic effect of Venolazine on RE patients after esophagogastric anastomosis is better than Esomeprazole,which can regulate serum inflammatory factors,CGRP,HO-1 and GSH levels,alleviate gastrointestinal injury,and improve clinical symptoms,with fewer adverse reactions and lower recurrence rate.
维普
万方数据